The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Open accessAbstract
Microtubule-associated protein tau is abnormally hyperphosphorylated and aggregated into neurofibrillary tangles in brains of individuals with Alzheimer's disease (AD) and other tauopathies. Tau pathology is critical to pathogenesis and correlates to the severity of dementia. However, the mechanisms leading to abnormal hyperphosphorylation are unknown. Here, we demonstrate that human brain tau was modified by O-GlcNAcylation, a type of protein O-glycosylation by which the monosaccharide β- N -acetylglucosamine (GlcNAc) attaches to serine/threonine residues via an O-linked glycosidic bond. O-GlcNAcylation regulated phosphorylation of tau in a site-specific manner both in vitro and in vivo . At most of the phosphorylation sites, O-GlcNAcylation negatively regulated tau phosphorylation. In an animal model of starved mice, low glucose uptake/metabolism that mimicked those observed in AD brain produced a decrease in O-GlcNAcylation and consequent hyperphosphorylation of tau at the majority of the phosphorylation sites. The O-GlcNAcylation level in AD brain extracts was decreased as compared to that in controls. These results reveal a mechanism of regulation of tau phosphorylation and suggest that abnormal hyperphosphorylation of tau could result from decreased tau O-GlcNAcylation, which probably is induced by deficient brain glucose uptake/metabolism in AD and other tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a reduction of glucose consumption induces an increase in phospho-Tau and A β accumulation (Fu et al., 2015; Liu et al., 2004).”
From Inhibition of the mitochondrial pyruvate carrier in astrocytes reduces amyloid and tau accumulation in the 3xTgAD mouse model of Alzheimer's disease (2024) · cites this paper as Liu et al., 2004
Experimental — accuracy not yet measuredIn the citing paper
“For example, reduced tau O-glycosylation could lead to increased phosphorylation, while the enhancement of O-glycosylation reduces the extent of tau phosphorylation [43–45].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [43]
In the citing paper
“As discussed above, a reciprocal relationship has been found between O-GlcNAcylation and phosphorylation on tau [43].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780
Self-citationA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Goedert, M., Spillantini, M. G., Cairns, N. J., & Crowther, R. A. (1992) · Neuron · doi:10.1016/0896-6273(92)90117-v · Cited by 1,122
Köpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779
Self-citation
Research works printed but not linked: 3
- Roos, M. D., Xie, W., Su, K., Clark, J. A., Yang, X., Chin, E., Paterson, A. J. & Kudlow, J. E. (1998) Proc. Assoc. Am. Physicians 110, 422-432.9756093
- Iqbal, K. & Grundke-Iqbal, I. (2000) Neurosci. News 3, 14-20.
- Xavier-Blaizot, A., Meguro, K., Millien, I., Baron, J.-C. & Chavoix, C. (2002) J. Neurosci. 21, 9166-9170.
Cited by
Sorted by citations
Items 201–300 of 781
Gong, C., Liu, F., Grundke, I., & Iqbal, K. (2006) · BioMed Research International · doi:10.1155/jbb/2006/31825 · Cited by 81
Self-citationWu, X., Piña-Crespo, J., Zhang, Y., Chen, X., & Xu, H. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.220313 · Cited by 82
Visualizing the Reaction Coordinate of an O-GlcNAc Hydrolase
He, Y., Macauley, M. S., Stubbs, K. A., Vocadlo, D. J., & Davies, G. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja9086769 · Cited by 77
Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease
Iqbal, K., Gong, C., & Liu, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.870156 · Cited by 76
Self-citationDisrupted glycosylation of lipids and proteins is a cause of neurodegeneration
Moll, T., Shaw, P. J., & Cooper‐Knock, J. (2019) · Brain · doi:10.1093/brain/awz358 · Cited by 79
O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease
Park, J., Lai, M. K. P., Arumugam, T. V., & Jo, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08584-0 · Cited by 79
Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration
Boyarko, B., & HOOK, V. Y. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.702788 · Cited by 81
Liu, X., Song, S., Chen, Z., Gao, C., Li, Y., Luo, Y., Huang, J., & Zhang, Z. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.031 · Cited by 78
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise
Xu, L., Liu, R., Qin, Y., & Wang, T. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00364-y · Cited by 78
p70 S6 Kinase and Tau in Alzheimer's Disease
Pei, J.-J., Björkdahl, C., Zhang, H., Zhou, X., & Winblad, B. G. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14405 · Cited by 75
The emerging link between O-GlcNAcylation and neurological disorders
Ma, X., Li, H., He, Y., & Hao, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2542-9 · Cited by 75
A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies
Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 76
The Role of Post-Translational Modifications on the Structure and Function of Tau Protein
Ye, H., Han, Y., Li, P., Su, Z., & Huang, Y. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02002-0 · Cited by 76
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Identification of new O-GlcNAc modified proteins using a click-chemistry-based tagging
Gurcel, C., Vercoutter‐Edouart, A., Fonbonne, C., Mortuaire, M., Salvador, A., Michalski, J., & Lemoine, J. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-1950-y · Cited by 74
Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease
Formichi, P., Battisti, C., Radi, E., & Federico, A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20602 · Cited by 80
Chen, S., Zhou, M. L., Sun, J., Guo, A. W., Fernando, R. L., Chen, Y., Peng, P., Zhao, G., & Deng, Y. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107668 · Cited by 72
Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain
Förster, S., Welleford, A. S., Triplett, J. C., Rukhsana Sultana, A., Schmitz, B., & Butterfield, D. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.014 · Cited by 73
Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage.
Liang, Z., Liu, F., Iqbal, K., Grundke-Iqbal, I., & Gong, C.-X. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1069 · Cited by 73
Self-citationJin, N., Yin, X., Gu, J., Zhang, X., Shi, J., Qian, W., Ji, Y., Cao, M., Gu, X., Ding, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645507 · Cited by 74
Self-citationPark, J., Han, D., Kim, K., KANG, Y. Y., & Kim, Y. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.10.003 · Cited by 71
Pinho, T. S., Correia, S. C., Perry, G., Ambrósio, A. F., & Moreira, P. I. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.037 · Cited by 70
Mapping of O-GlcNAc Sites of 20 S Proteasome Subunits and Hsp90 by a Novel Biotin-Cystamine Tag
Overath, T., Kuckelkorn, U., Henklein, P., Strehl, B., Bonar, D., Kloß, A., Siele, D., Kloetzel, P., & Janek, K. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015966 · Cited by 70
Jitonnom, J., Lee, V. S., Nimmanpipug, P., Rowlands, H. A., & Mulholland, A. J. (2011) · Biochemistry · doi:10.1021/bi101362g · Cited by 70
Andres, L. M., Blong, I. W., Evans, A. C., Rumachik, N. G., Yamaguchi, T., Pham, N. D., Thompson, P., Kohler, J. J., & Bertozzi, C. R. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00232 · Cited by 70
Ruegenberg, S., Horn, M., Pichlo, C., Allmeroth, K., Baumann, U., & Denzel, M. S. (2020) · Nature Communications · doi:10.1038/s41467-020-14524-5 · Cited by 71
REM Sleep Deprivation Impairs Learning and Memory by Decreasing Brain O-GlcNAc Cycling in Mouse
Kim, S.-M., Zhang, S., Park, J., Sung, H. J., Tran, T.-D. T., Chung, C., & Han, I. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01094-7 · Cited by 74
Role of Post‐translational Modifications in Alzheimer's Disease
Ramesh, M., Gopinath, P., & Govindaraju, T. (2019) · ChemBioChem · doi:10.1002/cbic.201900573 · Cited by 68
Chun, Y. S., Park, Y., Oh, H. G., Kim, T., Yang, H. O., Park, M. K., & Chung, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-140096 · Cited by 68
Arif, M., Wei, J., Zhang, Q., Liu, F., Basurto‐Islas, G., Grundke, I., & Iqbal, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.565358 · Cited by 68
Self-citationKumar, P., Jha, N. K., Jha, S. K., Ramani, K., & Ambasta, R. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140933 · Cited by 67
Jin, N., Wu, Q., Yin, X., Zhang, L., Iqbal, K., Grundke, I., Gong, C., & Liu, F. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1227 · Cited by 68
Self-citationA divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase
Stubbs, K. A., Zhang, N., & Vocadlo, D. J. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b516273d · Cited by 67
Lu, Q., Cheng, C., Xiong, Y., Li, G., Zhang, X., Zhang, Y., Wang, D., Zhu, Z., Li, X., Qing, G., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02643 · Cited by 66
Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes
Gloster, T. M., & Vocadlo, D. J. (2010) · Current Signal Transduction Therapy · doi:10.2174/157436210790226537 · Cited by 69
O-GlcNAcylation is required for B cell homeostasis and antibody responses
Wu, J.-L., Chiang, M.-F., Hsu, P., Tsai, D.-Y., Hung, K.-H., Wang, Y.-H., Angata, T., & Lin, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01677-z · Cited by 66
Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy
Ye, J., Wan, H., Chen, S., & Liu, G. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385847 · Cited by 74
Zhu, Y., Shan, X., Safarpour, F., Go, N. E., Li, N., Shan, A., Huang, M. C., Deen, M. C., Holicek, V., Ashmus, R. A., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00015 · Cited by 66
Fichou, Y., Al‐Hilaly, Y. K., Devred, F., Smet‐Nocca, C., Tsvetkov, P. O., Verelst, J., Winderickx, J., Geukens, N., Vanmechelen, E., Perrotin, A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0682-x · Cited by 67
Bartolomé-Nebreda, J. M., Trabanco, A. A., Velter, A. I., & Buijnsters, P. J. J. A. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1947242 · Cited by 59
New insight into protein glycosylation in the development of Alzheimer’s disease
Zhao, J., & Lang, M. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01617-5 · Cited by 63
Mitochondria in Alzheimer’s Disease Pathogenesis
Reiss, A. B., Gulkarov, S., Jacob, B., Srivastava, A., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2024) · Life · doi:10.3390/life14020196 · Cited by 71
Protein phosphatase 2A as therapeutic targets in various disease models
Baskaran, R., & Velmurugan, B. K. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.063 · Cited by 63
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Cantrelle, F., Loyens, A., Trivelli, X., Reimann, O., Despres, C., Gandhi, N. S., Hackenberger, C. P. R., Landrieu, I., & Smet‐Nocca, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.661368 · Cited by 63
Linking insulin with Alzheimer’s disease: emergence as type III diabetes
Ahmed, S. A. A., Mahmood, Z., & Zahid, S. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2352-5 · Cited by 65
Fluorescent biosensors for real-time tracking of post-translational modification dynamics
Aye-Han, N.-N., Ni, Q., & Zhang, J. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.07.009 · Cited by 61
Skorobogatko, Y. V., Deuso, J., Adolf-Bergfoyle, J., Nowak, M. G., Gong, Y., Lippa, C. F., & Vosseller, K. (2010) · Amino Acids · doi:10.1007/s00726-010-0645-9 · Cited by 60
Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial
Iqbal, K., Wang, X., Blanchard, J., Liu, F., Gong, C., & Grundke, I. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380962 · Cited by 61
Self-citationIntegration of O-GlcNAc into Stress Response Pathways
Fahie, K., Papanicolaou, K. N., & Zachara, N. E. (2022) · Cells · doi:10.3390/cells11213509 · Cited by 67
Chun, Y. S., Kwon, O.-H., & Chung, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.067 · Cited by 60
Chen, D., Juárez, S., Hartweck, L. M., Alamillo, J. M., Simón‐Mateo, C., Pérez, J. J., Fernández-Fernández, M. R., Olszewski, N. E., & Garcı́a, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9381-9387.2005 · Cited by 60
Dysregulation of energy metabolism in Alzheimer's disease
Yuan, Y., Zhao, G., & Zhao, Y. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12800-8 · Cited by 74
Hoyer, S., & Lannert, H. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_25 · Cited by 59
O-GlcNAcase: Promiscuous Hexosaminidase or Key Regulator of O-GlcNAc Signaling?
Alonso, J., Schimpl, M., & van Aalten, D. M. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.609198 · Cited by 59
Gatta, E., Lefebvre, T., Gaetani, S., Santos, M. D., Marrocco, J., Mir, A., Cassano, T., Maccari, S., Nicoletti, F., & Mairesse, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.006 · Cited by 62
Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 58
Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Vignini, A., Giulietti, A., Nanetti, L., Raffaelli, F., Giusti, L., Mazzanti, L., & Provinciali, L. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309030003 · Cited by 57
Glucose metabolism: A link between traumatic brain injury and Alzheimer’s disease
Xu, X., Yang, M.-S., Zhang, B., Niu, F., Dong, J., & Liu, B. (2020) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2020.10.001 · Cited by 59
Ahmed, T., Zahid, S., Mahboob, A., & Farhat, S. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160325121145 · Cited by 60
Opportunities for Therapeutic Modulation of O-GlcNAc
Cheng, S. S., Mody, A. C., & Woo, C. M. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00417 · Cited by 64
Losev, Y., Frenkel-Pinter, M., Abu-Hussien, M., Viswanathan, G. K., Elyashiv-Revivo, D., Geries, R., Khalaila, I., Gazit, E., & Segal, D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03643-3 · Cited by 52
Comparative glycoproteomics: approaches and applications
Wei, X. L., & Li, L. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln053 · Cited by 55
Elbaum, M. B., & Zondlo, N. J. (2014) · Biochemistry · doi:10.1021/bi500117c · Cited by 55
Elucidating Tau function and dysfunction in the era of cryo-EM
Lippens, G. M., & Gigant, B. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.008031 · Cited by 56
Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases
Pratt, M. R., & Vocadlo, D. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105411 · Cited by 56
Tau Aggregation and Toxicity in Tauopathic Neurodegenerative Diseases
Honson, N. S., & Kuret, J. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14409 · Cited by 54
O-GlcNAcylation of tubulin inhibits its polymerization
Ji, S., Kang, J. G., Park, S., Lee, J., Oh, Y. J., & Cho, J. W. (2010) · Amino Acids · doi:10.1007/s00726-010-0698-9 · Cited by 52
O-GlcNAcylation: key regulator of glycolytic pathways
Bacigalupa, Z. A., Bhadiadra, C., & Reginato, M. J. (2018) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-018-9742-3 · Cited by 52
DoesO-GlcNAc play a role in neurodegenerative diseases?
Lefebvre, T., Guinez, C., Dehennaut, V., Dekeyzer-Beseme, O., Morelle, W., & Michalski, J. (2005) · Expert Review of Proteomics · doi:10.1586/14789450.2.2.265 · Cited by 54
Losev, Y., Paul, A., Frenkel-Pinter, M., Abu-Hussein, M., Khalaila, I., Gazit, E., & Segal, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-39218-x · Cited by 50
Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network
Sonawane, S. K., & Chinnathambi, S. (2021) · Oncotarget · doi:10.18632/oncotarget.27963 · Cited by 51
The synaptic proteome in Alzheimer's disease
Chang, R. Y. K., Nouwens, A. S., Dodd, P. R., & Etheridge, N. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.04.009 · Cited by 52
Playing tag with quantitative proteomics
Iliuk, A. B., Galan, J. A., & Tao, W. A. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2386-0 · Cited by 51
Bourré, G., Cantrelle, F., Kamah, A., Chambraud, B., Landrieu, I., & Smet‐Nocca, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00595 · Cited by 57
Four-Repeat Tauopathies: Current Management and Future Treatments
VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 55
Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50
Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease
Marcus, J., & Schachter, J. B. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.626471 · Cited by 51
Ataxin-10 Interacts with O-Linked β-N-Acetylglucosamine Transferase in the Brain
März, P., Stetefeld, J., Bendfeldt, K., Nitsch, C., Reinstein, J., Shoeman, R. L., Dimitriades‐Schmutz, B., Schwager, M., Leiser, D., Özcan, S., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601563200 · Cited by 49
Francisco, H., Kollins, K. M., Varghis, N., Vocadlo, D. J., Vosseller, K., & Gallo, G. (2008) · Developmental Neurobiology · doi:10.1002/dneu.20695 · Cited by 48
Huang, X., Wang, F., Chen, W., Chen, Y., Wang, N., & von Maltzan, K. (2012) · Brain Research · doi:10.1016/j.brainres.2012.06.011 · Cited by 48
Bergeron‐Brlek, M., Goodwin‐Tindall, J., Cekic, N., Roth, C., Zandberg, W. F., Shan, X., Varghese, V., Chan, S., Davies, G. J., Vocadlo, D. J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507985 · Cited by 48
Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies
Fuster-Matanzo, A., Hernández, F., & Ávila, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030645 · Cited by 50
Duarte, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.044 · Cited by 49
Activation of Protein Phosphatase 2B and Hyperphosphorylation of Tau in Alzheimer's Disease
Qian, W., Yin, X., Hu, W. H., Shi, J., Gu, J., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100987 · Cited by 47
Self-citationMellone, M., Kestoras, D., Andrews, M. R., Dassie, E., Crowther, R. A., Stokin, G. B., Tinsley, J. M., Horne, G., Goedert, M., Tolkovsky, A. M., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4933-12.2013 · Cited by 44
Glycomics of pediatric and adulthood diseases of the central nervous system
Barone, R. M. E., Sturiale, L., Palmigiano, A., Zappia, M., & Garozzo, D. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.07.007 · Cited by 46
Memory and synaptic plasticity are impaired by dysregulated hippocampal O-GlcNAcylation
Yang, Y. R., Song, S., Hwang, H., Jung, J. H., Kim, S.-J., Yoon, S., Hur, J., Park, J.-I., Lee, C., Nam, D., et al. (2017) · Scientific Reports · doi:10.1038/srep44921 · Cited by 47
Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis
Muha, V., Authier, F., Szoke-Kovacs, Z., Johnson, S., Gallagher, J. R., McNeilly, A. D., McCrimmon, R. J., Teboul, L., & van Aalten, D. M. F. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100439 · Cited by 47
Glycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer’s Disease Brain
Suttapitugsakul, S., Stavenhagen, K., Donskaya, S., Bennett, D. A., Mealer, R. G., Seyfried, N. T., & Cummings, R. D. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100433 · Cited by 48
Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors
Lim, S., Haque, M. M., Nam, G., Ryoo, N., Rhim, H., & Kim, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920212 · Cited by 45
Yu, C., Si, T., Wu, W., Hu, J. N., Du, J., Zhao, Y., & Li, Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.101 · Cited by 52
Kao, H.-J., Huang, C., Bretaña, N. A., Lu, C.-T., Huang, K., Weng, S., & Lee, T.-Y. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s18-s10 · Cited by 52
dos Santos, J. P. A., Vizuete, A. F. K., Hansen, F., Biasibetti, R., & Gonçalves, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170211 · Cited by 46
Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders
Balana, A. T., & Pratt, M. R. (2021) · Biochemical Journal · doi:10.1042/bcj20200609 · Cited by 46
Disentangling tau: One protein, many therapeutic approaches
Lane‐Donovan, C., & Boxer, A. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00321 · Cited by 49
Wu, J.-L., Wu, H., Tsai, D.-Y., Chiang, M.-F., Chen, Y., Gao, S., Lin, C., Lin, C., Khoo, K., Chen, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms12526 · Cited by 45
Gratuze, M., Khoury, N. B. E., Turgeon, A., Julien, C., Marcouiller, F., Morin, F., Whittington, R. A., Marette, A., Calon, F., & Planel, E. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.10.004 · Cited by 47
Carbohydrate-based experimental therapeutics for cancer, HIV/AIDS and other diseases
Oppenheimer, S. B., Alvarez, M., & Nnoli, J. (2007) · Acta Histochemica · doi:10.1016/j.acthis.2007.08.003 · Cited by 46
Cryo-EM structure of human O-GlcNAcylation enzyme pair OGT-OGA complex
Lu, P., Liu, Y., He, M., Cao, T., Yang, M., Qi, S., Yu, H., & Gao, H. (2023) · Nature Communications · doi:10.1038/s41467-023-42427-8 · Cited by 49
Metadata
- Authors
- Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X.
- Affiliations
- Johns Hopkins University (US)
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314; and Department of Biological Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205
- Corresponding author
- Gong, Cheng-Xin
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-07-12
- Volume
- 101
- Issue
- 29
- Pages
- 10804-10809
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC490015
- OpenAlex
- W2164029759
- Cited by
- 775
- References
- 42
- Citations by year
- 2026: 29 · 2025: 50 · 2024: 38 · 2023: 36 · 2022: 44 · 2021: 63 · 2020: 57 · 2019: 38 · 2018: 46 · 2017: 45 · 2016: 33 · 2015: 23 · 2014: 36 · 2013: 24 · 2012: 35
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nanjing Medical University
- National Institutes of Health (HD13563)
- National Institute on Aging (AG19158, R01AG019158, AG16760, R01AG016760)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R37HD013563, HD13563)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- O-GlcNAcylation, tau protein, tau hyperphosphorylation, Alzheimer's disease, tauopathy, neurofibrillary tangles, O-glycosylation, glucose metabolism, brain glucose uptake
- MeSH terms
- Acetylglucosamine, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Brain, Female, Glycosylation, Humans, Male, Mice, Inbred C57BL, Middle Aged, Phosphorylation, Starvation, PC12 Cells, tau Proteins, Rats, Wistar, Mice, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
